Impact of Oocyte Extract Supplement on Quality of Life after Hepatectomy for Liver Tumours: A Prospective, Multicentre, Double-Blind Randomized Clinical Trial.
cholangiocarcinoma
hepatocellular carcinoma
liver surgery
oocyte extract
postoperative recovery
quality of life
supplementation therapy in liver surgery
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 May 2023
18 May 2023
Historique:
received:
28
03
2023
revised:
14
05
2023
accepted:
16
05
2023
medline:
22
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
Previous studies on oocyte extract supplementation showed benefits in patients with liver tumours. In this trial, we hypothesized that the oocyte extract supplement impacted the QoL after hepatectomy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. This was a multicentre, double-blind, randomized clinical trial designed to assess the QoL of patients receiving a supplement of oocyte extract or placebo postoperatively. QoL was assessed using the Short Form-36 questionnaire in participants randomly assigned to treatment (Synchrolevels) or placebo. All study personnel and participants were masked to treatment assignment. The endpoint was the change in the QoL score. Between June 2018 and September 2022, 66 of 128 expected patients were considered as per interim analysis, of which 33 were assigned to the treatment and 33 to the placebo group. Baseline and clinicopathological characteristics were similar between the two groups. In the treatment group, the health, mental and psychological status improved for many of the items considered, reaching statistical significance, while in the placebo group, those items either did not change or were impaired in comparison with the corresponding baseline. Supplementation with oocyte extract modifies QoL after liver surgery by enhancing functional recovery. Further in-depth studies are required to confirm this evidence.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies on oocyte extract supplementation showed benefits in patients with liver tumours. In this trial, we hypothesized that the oocyte extract supplement impacted the QoL after hepatectomy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
METHODS
METHODS
This was a multicentre, double-blind, randomized clinical trial designed to assess the QoL of patients receiving a supplement of oocyte extract or placebo postoperatively. QoL was assessed using the Short Form-36 questionnaire in participants randomly assigned to treatment (Synchrolevels) or placebo. All study personnel and participants were masked to treatment assignment. The endpoint was the change in the QoL score.
RESULTS
RESULTS
Between June 2018 and September 2022, 66 of 128 expected patients were considered as per interim analysis, of which 33 were assigned to the treatment and 33 to the placebo group. Baseline and clinicopathological characteristics were similar between the two groups. In the treatment group, the health, mental and psychological status improved for many of the items considered, reaching statistical significance, while in the placebo group, those items either did not change or were impaired in comparison with the corresponding baseline.
CONCLUSIONS
CONCLUSIONS
Supplementation with oocyte extract modifies QoL after liver surgery by enhancing functional recovery. Further in-depth studies are required to confirm this evidence.
Identifiants
pubmed: 37345146
pii: cancers15102809
doi: 10.3390/cancers15102809
pmc: PMC10216542
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncol Res. 2005;15(7-8):399-408
pubmed: 16491958
J Adv Pharm Technol Res. 2016 Oct-Dec;7(4):118-122
pubmed: 27833889
Arch Surg. 2009 Feb;144(2):167-72
pubmed: 19221329
J Clin Epidemiol. 1998 Nov;51(11):903-12
pubmed: 9817107
Qual Life Res. 1992 Jun;1(3):203-10
pubmed: 1363776
Oncologist. 2012;17(5):732-9
pubmed: 22511265
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Gene. 2021 Feb 5;768:145263
pubmed: 33122078
Support Care Cancer. 2008 Sep;16(9):1059-65
pubmed: 18197433
Clin Gastroenterol Hepatol. 2010 Jul;8(7):559-64.e1-10
pubmed: 20304101
J Gastroenterol Hepatol. 2007 Feb;22(2):197-203
pubmed: 17295871
Arch Surg. 2001 Jun;136(6):693-9
pubmed: 11387012
Curr Pharm Biotechnol. 2011 Feb 1;12(2):261-7
pubmed: 21043999
Liver Int. 2019 May;39 Suppl 1:143-155
pubmed: 30843343
Curr Pharm Biotechnol. 2015;16(9):782-92
pubmed: 26201607
Int J Mol Sci. 2019 Apr 30;20(9):
pubmed: 31052313
Semin Cancer Biol. 2022 Feb;79:83-90
pubmed: 32920125
Ann Surg. 2013 May;257(5):929-37
pubmed: 23426336
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3130-9
pubmed: 11124729
J Clin Epidemiol. 1998 Nov;51(11):1045-53
pubmed: 9817122
BMJ. 2010 Mar 23;340:c869
pubmed: 20332511
JAMA Netw Open. 2020 Mar 2;3(3):e200388
pubmed: 32129862
Psychooncology. 2004 Feb;13(2):73-9
pubmed: 14872525
J Natl Cancer Inst. 1992 Jul 1;84(13):994-5
pubmed: 1608056
Eur Rev Med Pharmacol Sci. 2021 Apr;25(8):3235-3245
pubmed: 33928609
Ann Oncol. 2022 Sep;33(9):878-892
pubmed: 35462007
World J Surg. 2014 Apr;38(4):958-67
pubmed: 24305919
Br J Surg. 2008 Jul;95(7):845-54
pubmed: 18496887
Curr Pharm Biotechnol. 2011 Feb 1;12(2):254-60
pubmed: 21044000
J Clin Epidemiol. 1998 Nov;51(11):1037-44
pubmed: 9817121
Surgery. 2011 May;149(5):713-24
pubmed: 21236455
Cancer Lett. 1988 Aug 30;41(3):265-70
pubmed: 3409205
Anticancer Res. 2008 May-Jun;28(3A):1575-80
pubmed: 18630514
Liver Cancer. 2016 Nov;6(1):44-50
pubmed: 27995087
Cell Death Differ. 2008 Aug;15(8):1211-20
pubmed: 18274553
Int J Biochem Cell Biol. 2011 Jul;43(7):1052-8
pubmed: 20460170
Surg Oncol. 2012 Mar;21(1):e23-30
pubmed: 22104002
Nat Med. 2011 Dec 11;18(1):91-9
pubmed: 22157679